2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR
  5. GCGR Antagonist

GCGR Antagonist

GCGR Antagonists (28):

Cat. No. Product Name Effect Purity
  • HY-116854
    NNC 92-1687
    		Antagonist 98.74%
    NNC 92-1687 is a non-peptide competitive human glucagon receptor antagonist (IC50=20 μM; Ki=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes.
  • HY-107129
    MK-3577
    		Antagonist
    MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research.
  • HY-50663
    MK 0893
    		Antagonist 99.86%
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
  • HY-101116
    GLP-1R Antagonist 1
    		Antagonist 99.84%
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM.
  • HY-P1141
    GLP-1(9-36)amide
    		Antagonist 99.78%
    GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor.
  • HY-19904
    Adomeglivant
    		Antagonist 99.63%
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.
  • HY-P1023
    VIP(6-28)(human, rat, porcine, bovine)
    		Antagonist 99.69%
    VIP(6-28)(human, rat, porcine, bovine) is an effective antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) on cAMP.
  • HY-19947
    PF-06291874
    		Antagonist 99.18%
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM).
  • HY-12525
    LGD-6972
    		Antagonist ≥98.0%
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research.
  • HY-103547
    L-168049
    		Antagonist 99.93%
    L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively.
  • HY-50159
    Glucagon receptor antagonists-3
    		Antagonist 98.52%
    Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.
  • HY-50158
    Glucagon receptor antagonists-2
    		Antagonist 99.23%
    Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.
  • HY-P99383
    Volagidemab
    		Antagonist 98.43%
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).
  • HY-P1143A
    [Des-His1,Glu9]-Glucagon amide TFA
    		Antagonist 99.62%
    [Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes.
  • HY-148844
    GCGR antagonist 2
    		Antagonist 99.76%
    GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an Kd value of 2.3 nM, and inhibits rat receptor with an IC50 value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis.
  • HY-P1141A
    GLP-1(9-36)amide TFA
    		Antagonist 98.00%
    GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor.
  • HY-119739
    Skyrin
    		Antagonist
    Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells.
  • HY-10036
    Glucagon receptor antagonists-1
    		Antagonist 98.65%
    Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.
  • HY-P2497
    Exendin (5-39)
    		Antagonist 99.81%
    Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats.
  • HY-128781
    Glucagon receptor antagonists-5
    		Antagonist
    Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM).